|Bid||1.1200 x 800|
|Ask||1.1400 x 3100|
|Day's Range||1.0250 - 1.1500|
|52 Week Range||1.0250 - 3.6500|
|Beta (5Y Monthly)||0.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.32|
Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 (a proprietary oral transmucosal film formulation of DMT) demonstrated that 160mg of VLS-01 reached exposure levels comparable to 30mg of IV DMT. Acceptance of three non-clinical poster presentations at upcoming medical meetings, including non-clinical data for RL-007 and two nove
Key Takeaways; Cannabis Sector Trulieve is challenging 280E cannabis taxation, seeking $143 million federal tax refund. TerrAscend raised its full year 2023 guidance, triggering a surge in stock price. Red White & Bloom won the race to acquire Aleafia Health after an earlier stumble. Key Takeaways; Psychedelic Sector Atai strengthened investment in IntelGenx technologies. Awakn’s […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.
This press release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues ("NI 62-103"), in connection with certain transactions completed by atai Life Sciences AG (Nasdaq: ATAI) ("atai") and IntelGenx Technologies Corp. (the "IntelGenx"), that were previously described in a press release issued by IntelGenx on August 31 2023.